Show MeBradykinesia and dyskinesia are opposite movement problems in Parkinson's disease. Bradykinesia means too little movement: slowness, smaller steps, reduced arm swing, and a quiet face caused by dopamine loss in the basal ganglia. Dyskinesia means too much movement: involuntary jerky or writhing motions, usually appearing when levodopa levels peak, caused by long-term dopamine replacement rather than by Parkinson's itself. In practice, bradykinesia is a core symptom the disease produces, while dyskinesia is largely a complication of treating it, and the two can coexist in the same patient on the same day.
The mechanism: why one brain produces both too little and too much
Parkinson's disease strips dopamine-producing neurons from the substantia nigra. By the time motor signs appear, roughly 50 to 60 percent of those neurons are already gone and striatal dopamine is down about 80 percent, per decades of postmortem work summarized in landmark neuropathology reviews. The basal ganglia rely on dopamine to scale movement: to pick a motor program, amplify it, and release it at the right size. Losing dopamine narrows that channel, and bradykinesia is the clinical result. Movements are not just slower; they are smaller in amplitude, which is why Parkinsonian handwriting shrinks (micrographia) and steps shorten before walking speed visibly drops.
Dyskinesia arises from a different process. When levodopa is given, surviving neurons convert it to dopamine, but they cannot store it the way healthy neurons do. Dopamine levels therefore swing instead of holding steady. Over years, the striatal medium spiny neurons that carry movement commands become sensitized to these pulses. The result is a dysregulated output that over-fires rather than under-fires. In plain terms: the same drug that rescues slowness can, after years of use, push the motor system past normal into excess movement.
This distinction matters because it predicts timing. Bradykinesia tracks how much dopamine is available, so it worsens as a dose wears off. Dyskinesia tracks how abruptly dopamine arrives, so it clusters when levels peak.
Quantified comparison: how the two differ in numbers
| Feature | Bradykinesia | Dyskinesia |
|---|---|---|
| Core direction | Too little movement (hypokinesia) | Too much movement (hyperkinesia) |
| Primary cause | Dopamine neuron loss in substantia nigra | Long-term levodopa exposure and pulsatile stimulation |
| Typical onset | Before diagnosis; present in over 90% at diagnosis | After roughly 4 to 6 years of levodopa in about 40 to 50% of patients |
| Timing within a dose | Worst at end of dose ("wearing off") | Worst at peak dose, 30 to 90 minutes after a dose |
| Voluntary control | Can be overcome with effort and cueing | Cannot be voluntarily suppressed |
| Speed of movement | Reduced amplitude and velocity | Involuntary, often rhythmic or writhing |
| Prevalence after 10 years of treatment | Universal or near-universal | Up to 80 to 90% in younger-onset patients |
| Main treatment lever | More dopaminergic therapy, dose timing | Lower dose per intake, continuous delivery, amantadine |
The numbers reconcile like this: bradykinesia is present in the great majority of patients from diagnosis onward, while dyskinesia emerges later and rises with cumulative levodopa exposure, so a patient can have near-universal bradykinesia and a 40 to 50 percent risk of dyskinesia at the same five-year mark. These are population ranges, not individual predictions, and younger age at onset roughly doubles the dyskinesia risk.
Bradykinesia in detail: what it actually looks like and how it is measured
Bradykinesia is the most disabling of the cardinal features because it shrinks the whole movement repertoire. Clinicians grade it on the MDS-Unified Parkinson's Disease Rating Scale, part III, using finger tapping, hand movements, and pronation-supination tasks scored 0 to 4 per side. A widely used motor cutoff for defining Parkinsonism is bradykinesia plus at least one of rigidity or rest tremor, with scores of 2 or more on the relevant items.
Beyond the exam, quantitative tools capture the amplitude deficit. Finger-tapping keyboards measure inter-tap intervals; a healthy adult taps at roughly 4 to 6 taps per second, while untreated Parkinsonian patients drop toward 2 to 3 and show progressive decrement across a 10-second burst. Gait analysis shows step length falling from about 70 centimeters to 40 to 50 centimeters. Speech becomes hypophonic, with voice intensity dropping 2 to 4 decibels and a monotone pitch contour.
The non-obvious detail is that bradykinesia is not purely a speed problem. It is a scaling problem. Patients can move quickly for a single repetition; the deficit appears when they must sustain or repeat the movement, which is why the UPDRS scoring rewards observing decrement over a burst rather than a single tap. This is the corrected misconception: bradykinesia is not simply "slow," it is "fading amplitude under repetition."
Dyskinesia in detail: chorea, dystonia, and the peak-dose pattern
Dyskinesia most often takes the form of chorea, brief irregular jerks that flow from one body part to another, and dystonia, sustained twisting postures. The classic pattern is peak-dose dyskinesia, appearing 30 to 90 minutes after a levodopa dose and fading as the dose wanes. Less common patterns include diphasic dyskinesia, which appears at both the start and end of a dose, and off-period dystonia, which occurs when dopamine is lowest and typically affects the feet in the early morning.
Severity is graded by the Abnormal Involuntary Movement Scale or the dyskinesia items of the UPDRS, and by patient-reported hours per day. A patient with 4 to 6 waking hours of troublesome dyskinesia is generally a candidate for therapy adjustment. Roughly 10 to 30 percent of patients develop dyskinesia that is troublesome enough to limit dosing, and that subgroup drives most medication changes.
The edge case worth flagging: dyskinesia can be mistaken for worsening Parkinson's, leading to an inappropriate dose increase. This is a dangerous error because more levodopa worsens peak-dose dyskinesia. Distinguishing the two by timing is the single most useful clinical skill here.
Telling them apart moment to moment: a timeline within the day
The time course is the practical key. Bradykinesia and dyskinesia live at opposite ends of the levodopa cycle, and mapping a patient's day reveals which is which.
| Time in dose cycle | Dopamine state | Typical bradykinesia | Typical dyskinesia |
|---|---|---|---|
| 0 to 15 minutes after dose | Rising | Present, "off" | Absent |
| 30 to 90 minutes | Peak | Improved | Peak-dose dyskinesia |
| 2 to 4 hours | Falling | Returning | Fading or diphasic |
| 4 to 6 hours | Low or "off" | Worst, "wearing off" | Off-period dystonia |
| Overnight | Lowest | Severe stiffness, slow turning | Early-morning foot dystonia |
| After dose adjustment | Altered | Improves with more coverage | Worsens with higher peaks |
Track the clock for three days and the pattern usually sorts itself out. If the involuntary movements appear within an hour of a dose and melt away before the next, it is peak-dose dyskinesia. If slowness and stiffness dominate just before each dose, that is wearing-off bradykinesia.
What to actually do: concrete steps for patients and caregivers
The first positive action is to keep a timed symptom diary for at least 72 hours. Record dose times, when slowness peaks, and when involuntary movements start and stop. Bring it to the neurologist; it changes management more than any single exam.
The second is to report dyskinesia that interferes with function rather than staying silent about it. Many patients under-report because they prefer any movement to stiffness, so troubling dyskinesia is often missed. A good rule: if dyskinesia lasts more than 25 percent of the waking day or causes injury, it deserves a therapy review.
The third is to avoid self-adjusting doses based on a single bad day. Dyskinesia and bradykinesia respond to opposite changes, so a dose bump for slowness can trigger a dyskinetic storm.
Red-flag warnings that warrant urgent contact with the care team:
- Dyskinesia causing falls, head injury, or inability to eat or drink
- New confusion, hallucinations, or severe agitation alongside movement changes
- Sudden severe worsening of stiffness with fever, which can signal a dopamine agonist withdrawal or neuroleptic malignant syndrome picture
- Inability to swallow or clear secretions
- Dyskinesia so continuous that sleep is lost for more than two nights
- Chest pain, breathlessness, or new swelling, which may reflect dopaminergic complications rather than the movement disorder itself
Treatment trade-offs: the balance between under- and over-dosing
The therapeutic problem is a narrow window. Too little dopamine produces bradykinesia; too much, delivered in pulses, produces dyskinesia. Modern strategies aim to smooth delivery rather than simply raise or lower the total.
| Strategy | Effect on bradykinesia | Effect on dyskinesia | Practical trade-off |
|---|---|---|---|
| Increase levodopa dose | Improves | Worsens | Useful in early disease, problematic later |
| Divide doses into smaller, more frequent pills | Maintains coverage | Reduces peaks | More pill burden, adherence risk |
| Add COMT or MAO-B inhibitor | Prolongs coverage | May reduce wearing-off and off time | Can increase dyskinesia if levodopa not reduced |
| Amantadine | Neutral to modest benefit | Reduces dyskinesia by roughly 30 to 60% in trials | Side effects include ankle swelling and confusion |
| Deep brain stimulation of the subthalamic nucleus | Improves | Reduces by 50 to 70% in well-selected patients | Surgery risk, programming visits, cognitive screening |
| Continuous intestinal levodopa-carbidopa gel | Improves | Reduces off time and dyskinesia | Requires a pump and tube, infection risk |
Per the 2019 International Parkinson and Movement Disorder Society evidence-based review, amantadine carries a "clinically useful" designation for dyskinesia, and deep brain stimulation has the strongest evidence for reducing both motor fluctuations and dyskinesia in appropriately selected patients. The key point is that every intervention trades one symptom for another, which is why the timed diary and a specialist review matter more than any single drug choice.
Limits of what we know
The mechanism linking pulsatile dopamine to dyskinesia is well supported, but the exact molecular switch that sensitizes striatal neurons remains an active hypothesis. Not all patients who take levodopa for 20 years develop dyskinesia, and not all with dyskinesia have severe bradykinesia, so individual biology clearly matters. Genetic factors, age at onset, and sex all influence the risk. For now, the clinical lesson is stable: bradykinesia and dyskinesia are opposites to be balanced, not enemies to be defeated separately, and the timing diary is the tool that tells them apart.